.Attribute Medicine, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin resulted in strengthened progression-free and also overall survival, resulting in FDA approval as well as a brand new treatment option for patients.